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Abstract
Background: Imatinib, a tyrosine kinase inhibitor currently approved for treatment of several
malignancies, has been shown to be a substrate for multiple efflux-transporter proteins, including
ABCB1 (P-glycoprotein) and ABCG2 (BCRP). The effect of inhibiting these transporters on tissue
exposure to imatinib remains unclear.
Objective: To assess the role of these transporters on drug disposition, 50 mg/kg imatinib was
administered to Balb/C mice, 30 minutes after receiving tariquidar (10 mg/kg), an inhibitor of both
ABCB1 and ABCG2, or vehicle, via oral gavage.
Methods: Quantitative determination of imatinib in mouse plasma, liver and brain was performed
using a newly-developed and validated liquid-chromatography-mass spectrometric method.
Results: Exposure to imatinib was 2.2-fold higher in plasma, liver and brain in mice that received
tariquidar, as compared to those that received the vehicle (P = 0.001). The peak plasma
concentration did not increase substantially, suggesting that tariquidar is affecting the distribution,
metabolism and/or excretion of imatinib, rather than absorption. Though tariquidar increased the
absolute exposure of imatinib, the brain-to-plasma ratio of imatinib was unaffected.
Conclusion: This study suggests that intentional inhibition of ABCB1 and ABCG2 function at the
blood-brain barrier is unlikely to significantly improve clinical outcome of imatinib with currently
used dosing regimens.
Background
Imatinib mesylate is an orally administered tyrosine
kinase inhibitor, currently FDA approved for the treat-
ment of Philadelphia chromosome-positive chronic mye-
loid leukemia (targeting Brc-Abl) and unresectable and/or
metastatic malignant gastrointestinal stromal tumors (tar-
geting c-KIT) [1]. This agent is also currently under inten-
sive investigation in other tumor types, most notably as a
single agent or in combination with hydroxyurea for the
treatment of gliomas. However, there has been limited
clinical success reported to date [2,3].
Imatinib was initially determined to be a substrate for
ABCB1 (P-glycoprotein) in vitro [4]. Subsequently, it was
demonstrated that the in vivo distribution of imatinib is
limited by ABCB1-mediated efflux, resulting in limited
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topography studies with [N-11C-methyl]-imatinib have
confirmed limited brain penetration in primates [6].
However, ABCB1 is not the sole transporter expressed in
the blood-brain barrier that may limit the brain distribu-
tion of imatinib. In particular, imatinib is both an inhibi-
tor [7] and substrate [8] of ABCG2 (BCRP). Experiments
comparing the plasma and brain pharmacokinetics of
imatinib following i.v. administration of radiolabeled
drug to wild-type, Abcb1 knockout and Abcg2 knockout
mice have confirmed a role of these transporter proteins
in limiting brain exposure [9].
The potential influence of these efflux transporters is not
limited to brain exposure. For example, ABCB1 and
ABCG2 are also highly expressed in the small intestine,
bile canaliculi of the liver and numerous other normal tis-
sues [10,11]. In addition, expression of these proteins in
human tumors has been associated with development of
multidrug resistance [12]. Furthermore, in vitro studies
have suggested that long-term treatment with imatinib
leads to increased expression of both ABCB1 and ABCG2,
resulting in decreased intracellular drug accumulation
[13]. As such, it is of great interest to identify and charac-
terize inhibitors of ABCB1 and ABCG2 in vivo that could
potentially be used to intentionally alter the pharmacoki-
netics of and/or improve response to therapy with anti-
cancer ABCB1 and ABCG2 substrates [11].
Several transporter inhibitors have previously been evalu-
ated in preclinical models, including the ABCB1 inhibi-
tors valspodar and zosuquidar, the ABCG2 inhibitor
pantoprazol and the dual ABCB1/ABCG2 inhibitor elacri-
dar [9,14]. Tariquidar, an orally available anthranilic acid
derivative, has been shown to be an inhibitor of both
ABCB1 and ABCG2 [15]. It is currently in clinical trials
evaluating its utility as an inhibitor of ABCB1, in an effort
to overcome resistance associated with anticancer chemo-
therapy [16]. Here, we evaluated the effect of tariquidar
on the disposition of imatinib in mice, in order to provide
a pharmacokinetic rationale for attempts to improve the
agent's low brain penetration.
Methods
Chemicals and reagents
Imatinib mesylate was supplied by Novartis (East Hano-
ver, NJ). Tariquidar was supplied by Dr. Susan Bates (NCI,
Bethesda, MD). Glucose, harmine, absolute ethanol and
ammonium acetate were purchased from Sigma-Aldrich
(St. Louis, MO). Formic acid (98%) was obtained from
Fluka (through Sigma-Aldrich). Methanol (J.T. Baker,
Phillipsburg, NJ) was of HPLC grade. Deionized water
was generated with a Hydro-Reverse Osmosis system
(Durham, NC) connected to a Milli-Q UV Plus purifying
system (Billerica, MA). Blank mouse plasma was pur-
chased from Innovative Research (Southfield, MI).
Sample Preparation
Unknown and quality control (QC) plasma samples were
thawed at room temperature, vortex mixed for 20 sec-
onds, and 100 μL were transferred to a polypropylene cen-
trifuge tube. For analysis of unknown tissue samples,
approximately 100 mg of tissue were accurately weighed
and water added (5 μL per mg). After vortex-mixing, sam-
ples were homogenized using a PowerGen 125, while
kept on ice. One hundred μL of homogenate was trans-
ferred to a clean polypropylene centrifuge tube for further
processing. To each tube, including calibrators (10, 25,
50, 100, 500 and 1000 ng/mL) and QC samples (30, 450,
800 and 18,000 ng/mL), 250 μL of methanol (containing
25 ng/mL of internal standard, harmine) was added. All
tubes were capped, vortex-mixed for 5 min and then cen-
trifuged for 5 min at 18,000 × g. Following centrifugation,
the supernatant was transferred to a vial for injection.
Either 5 or 10 μL of the supernatant was injected for tissue
or plasma samples, respectively. Calibration curves and
QC samples were prepared in both brain and liver, for tis-
sue sample analysis. The working ranges for liver and
brain were 0.125–100 and 0.125–25 ng/mL, respectively.
Equipment
High performance liquid chromatography was carried out
on an Agilent 1100 system (Agilent Technology, Palo
Alto, CA), coupled with a single-quadrupole mass spec-
trometer, utilizing electrospray ionization in positive
mode. Samples were cooled to 4°C in a thermostated
autosampler and the column compartment, containing a
Waters SymmetryShield RP8 column (2.1 × 50 mm, 3.5
μm), was maintained at 35°C. Samples were eluted using
a gradient mobile phase, comprised of 10 mM ammo-
nium acetate with 0.1% formic acid and methanol, run-
ning at a flow rate of 0.35 mL/min for 10 min, including
re-equilibration. Mass spectrometric conditions were as
follows: fragmentor, 150 V; gain, 2; drying gas flow, 10 L/
min; drying gas temperature, 300°C; nebulizer pressure,
40 psi; and capillary voltage, 1500 V. Selected-ion moni-
toring was accomplished at m/z 494.2 for imatinib and m/
z 213.1 for the internal standard. The chromatographic
data were acquired and analyzed using the Chemstation
software package (Agilent).
Validation procedures
Calculation of accuracy and precision was carried out
according to procedures reported in detail previously [17].
Calibration samples were prepared fresh each day in the
relevant matrix and frozen QC samples were defrosted
and analyzed. A 1/x2 weighting scheme was employed in
the generation of standard curves to account for concen-
tration dependent variance. Detector response for plasmaPage 2 of 7
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range of 10–1000 ng/mL. Plasma accuracy and precision
were evaluated with QC samples. Overall, the assay was
found to be accurate (deviation of less than 10% for QCs)
and precise (within run precision <10%, between run pre-
cision <12.6%) for plasma, liver, and brain.
Animals
All experiments were performed on six-week old, male,
Balb/C mice obtained from Charles River Laboratories
(Wilmington, MA). The mice weighed approximately 15
to 20 g at the time of study. All mice were allowed unlim-
ited access to water and rodent chow prior to, and during
the experiment. Blank mouse liver and brain samples
were harvested from surplus mice following euthanasia.
NCI-Frederick is accredited by AAALAC International and
follows the Public Health Service Policy for the Care and
Use of Laboratory Animals. Animal care was provided in
accordance with the procedures outlined in the "Guide for
Care and Use of Laboratory Animals" (National Research
Council; 1996; National Academy Press; Washington,
DC). The study design and protocol were approved by the
NCI Animal Care and Use Committee (Bethesda, MD).
Experimental Design
Imatinib was dissolved in sterile water to make a 10 mg/
mL dosing solution. Tariquidar was prepared as a 2 mg/
mL solution in water with 5% glucose. Mice received
either 10 mg/kg tariquidar or the vehicle (5 mL per kg
weight) [15] 30 minutes prior to 50 mg/kg of imatinib
[18]. All compounds were administered via oral gavage.
At each time point, three mice in each treatment group
were anesthetized with isoflurane, and bled via cardiac
puncture into a tube containing sodium heparin as an
anticoagulant. Blood samples were centrifuged at 18,000
× g for 5 minutes at 4°C, the plasma layer transferred to a
cryovial and frozen. Following euthanasia by cervical dis-
location, brain and liver tissues were excised and snap-fro-
zen. All samples were stored at -80°C until the time of
analysis.
Statistical and pharmacokinetic analysis
Concentration-time data were evaluated using a non-
compartmental approach, with WinNonlin 5.0 (Phar-
sight, Mountain View, CA), using the mean concentration
(n = 3) at each time point. The peak plasma concentration
(Cmax) and the time to peak plasma concentration (Tmax)
are reported as observed values. The area under the curve
(AUC) was calculated using the linear trapezoidal method
from time zero to the time of the last sample with meas-
urable drug concentration. To allow for direct comparison
between the two groups and characterization of the termi-
nal phase for the imatinib alone arm, the 24-hour plasma
and liver samples, along with the 4-hour brain samples
were estimated at LLQ/2, as drug was detectable, but
measured concentrations were below the limit of quanti-
tation. Bailer's method was employed to assess the vari-
ance, allowing for comparison of exposure between the
two dose groups. The significance of the difference in AUC
was evaluated by a Z-test. Brain concentrations were cor-
rected for drug in the brain vascular space, by subtracting
1.4% of the plasma concentration from the measured
brain concentration for each animal [5]. Brain-to-plasma
concentration ratios were calculated for each animal at the
2-hour time point, and the groups compared using a t-
test. All statistical tests were performed in Microsoft Excel
2004 (Redmond, WA). P-values < 0.05 were considered
significant.
Results
The administration of oral tariquidar 30 minutes prior to
an oral dose of imatinib resulted in a significant increase
in systemic exposure to imatinib (Table 1; Figure 1). Tar-
iquidar increased the peak plasma concentration of imat-
inib by 19% (6,813 ± 1,548 vs 5,711 ± 1,472 ng/mL, P =
ns), with no apparent change in the rate of absorption, as
judged from the similar times to peak concentration (0.17
hours). In contrast, the AUC0–24 for imatinib was 2.2-fold
higher in mice pretreated with tariquidar compared to the
vehicle (26,725 vs 12,168 hr*ng/mL, P = 0.001). In liver
tissue, tariquidar increased the peak concentration by
75% (46,139 vs 26,280 ng/g) and the AUC0–24 was also
2.2-fold higher (153,209 vs 68,331 hr*ng/mL, P <
0.00001). The maximal corrected concentration of imat-
inib achieved in brain tissue was 114% higher in the imat-
inib plus tariquidar group (417 vs 195 ng/g), and the
AUC0–4 was 2.2-fold higher (417 vs 195 hr*ng/mL, P =
0.00002). No imatinib was detectable in the brain within
the first 5 minutes after administration in either group,
and the maximal brain concentration was observed after
two hours in both groups. The brain-to-plasma ratio of
imatinib 2 hours after administration did not differ signif-
icantly between the two groups (P = 0.83), and similar
brain-to-plasma AUC0–4 ratios were observed for each
group (0.070 for imatinib plus vehicle versus 0.078 for
imatinib plus tariquidar). In addition, the liver-to-plasma
AUC0–24 ratios did not differ significantly between the two
groups.
Discussion
The current study indicates that administration of the dual
ABCB1 and ABCG2 inhibitor tariquidar results in a statis-
tically significantly increase in plasma, liver and brain
exposure to imatinib. Since imatinib is known to have
very high bioavailability (approximately 98%) [1], it is
likely that the difference in plasma AUC is due to modi-
fied distribution and/or elimination of the drug, rather
than a change in the extent of intestinal absorption. This
hypothesis is supported by the fact that tariquidar
increased the peak plasma concentration of imatinib byPage 3 of 7
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Concentration-time profiles of imatinib in A. plasma, B. liver and C. brain, for the imatinib plus vehicle group (solid line) and the imatinib plus tariquida  group (dashed line)Figure 1
Concentration-time profiles of imatinib in A. plasma, B. liver and C. brain, for the imatinib plus vehicle group 
(solid line) and the imatinib plus tariquidar group (dashed line). Error bars for each timepoint represent the standard 
error.
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icant. As expected, there was also no apparent change in
the rate of absorption. Considering that imatinib is
effluxed by both ABCB1 and ABCG2, the almost complete
bioavailability may seem somewhat surprising. However,
it is possible that the high concentrations of imatinib in
the gut are actually leading to localized inhibition of these
transporters, as has been suggested by inhibition data [7].
Inhibition of ABCB1 and ABCG2 by tariquidar may also
alter the extent of imatinib metabolism. Bihorel et al.
noted an increase in plasma concentrations of imatinib
metabolites in both Abcb1a/1b knockout and Abcg2
knockout mice; however, co-administration of elacridar,
another dual ABCB1 and ABCG2 inhibitor, did not alter
the concentrations of imatinib metabolites [19]. There-
fore, it is unclear whether this observation may arise due
to a compensatory mechanism in the knockout mice.
The brain-to-plasma concentration ratio of imatinib 2
hours after administration was not significantly affected
by tariquidar. In addition, the AUC0–4 ratio for brain-to-
plasma was similar in the presence or absence of tariqui-
dar. This suggests that, rather than modifying the blood-
brain barrier directly, tariquidar may simply be increasing
plasma concentrations of the drug, leading to saturation
of these efflux transporters at this site. The AUCs of imat-
inib in plasma and both of the tissues studied were 2.2-
fold higher following pre-treatment with tariquidar. If
modulation at the blood-brain barrier were occurring,
independent of increased plasma concentrations of drug,
it was hypothesized that the brain accumulation would be
greater, not merely the same, as the increase in plasma.
Initial comparison of the inhibitory effects of tariquidar
toward ABCB1 and ABCG2, as compared to elacridar, in
the context of imatinib disposition, may suggest that tar-
iquidar is less potent, in spite of previously published data
that supports the opposite [20]. Specifically, elacridar has
been shown to result in a 9.3-fold increase in the brain-to-
plasma concentration ratio, as compared to administra-
tion of imatinib alone [14]. However, those experiments
utilized significantly lower doses of imatinib as compared
to the present study (12.5 versus 50 mg/kg), and the abso-
lute concentrations of drug in brain were not stated.
Hence, it is possible that the higher imatinib dose utilized
in the current study results in higher plasma concentra-
tions of drug and, therefore, saturation of drug efflux at
the blood-brain barrier. In this context, it is particularly
noteworthy that single dose plasma pharmacokinetics of
imatinib in humans at the recommended oral dose of 400
mg per day results in overall drug exposure that is very
similar to that found in the current study for mice (24.8 ±
7.4 versus 26.3 ± 4.6 h* μg/mL) [1].
Direct comparison between this study and prior experi-
ments investigating the effect of ABC transporter inhibi-
tors on imatinib pharmacokinetics are difficult due to a
variety of reasons. The current study employed oral dosing
at 50 mg/kg of imatinib, in an effort to closely mimic the
Table 1: Pharmacokinetics of imatinib in Balb/C mice in the presence and absence of tariquidar
Imatinib alone Imatinib + Tariquidar
Plasma Mean SD Mean SD Fold Change P-value
Cmax (ng/mL) 5,710.5 1,472.3 6,813.2 1,547.9 1.19 -
Tmax
(hr)
0.17 - 0.17 - - -
AUC0–24
(hr*ng/mL)
12,167.5 - 26,724.6 - 2.20 0.001
Liver Mean SD Mean SD Fold Change P-value
Cmax
(ng/g)
26,279.7 4,560.2 46,139.1 11,000.6 1.76 -
Tmax
(hr)
0.25 - 0.17 - - -
AUC0–24
(hr*ng/g)
68,330.8 - 153,209.2 - 2.24 < 0.00001
Brain Mean SD Mean SD Fold Change P-value
Cmax
(ng/g)
194.7 27.2 417.0 116.6 2.14 -
Tmax
(hr)
2 - 2 - - -
AUC0–4
(hr*ng/g)
574.23 - 1,277.7 - 2.23 0.00001Page 5 of 7
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12.5 mg/kg of imatinib intravenously (in combination
with elacridar) [9]. These authors also examined the effect
of oral pantoprazole on the pharmacokinetics of 100 mg/
kg oral imatinib [9]. Though the increase in brain expo-
sure to imatinib was reported to be higher with oral
administration, as compared to i.v., this was only meas-
ured at 4 hours post-imatinib, and the analysis was based
only on measurement of total radioactivity. As such, it is
impossible to determine whether the higher radioactivity
in the brain is due to the parent drug only or the parent
drug plus metabolites.
Mistry et al. have demonstrated that the inhibitory effect
of tariquidar on drug efflux in vitro persists for over two
hours [15]. In healthy volunteers, a dose of 2 mg/kg i.v. or
≥ 200 mg orally, resulted in 100% inhibition of ABCB1 in
CD56+ lymphocytes for over 24 hours. The maximal
effect was observed between 2 and 6 hours after adminis-
tration of tariquidar. In the current study, tariquidar was
administered 30 minutes prior to imatinib administration
in an effort to ensure sufficient distribution and inhibitory
effects.
Conclusion
In conclusion, oral administration of tariquidar prior to
oral imatinib resulted in increased imatinib exposure in
plasma and tissues, including brain. The increase in brain
exposure appears to be directly related to the increase in
plasma concentrations of the drug, at a dose comparable
to that used clinically. This further substantiates the possi-
bility that ABC transporters localized in the blood brain
barrier are more resistant to inhibition than at other tissue
sites such as the intestine and liver [20]. In a clinical set-
ting, the currently observed increase in plasma AUC could
result in increased toxicity, as has been observed previ-
ously with the use of ABCB1 inhibitors [21]. One strategy
that has been employed is dose reduction prior to com-
bining the ABCB1 and ABCG2 substrate with the trans-
porter inhibitor to avoid this toxicity.
Based on our findings, simply doubling the dose of imat-
inib without addition of an inhibitor would likely result
in a similar increase in overall brain exposure, due to
increased plasma concentrations of drug. It should be
anticipated that inhibition of ABCB1 and ABCG2 func-
tion at the blood-brain barrier will not result in a selective
increase in brain penetration or improved clinical out-
come, beyond that achieved through dose-escalation.
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